Biomerica, Inc. announced that its inFoods®? IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The publication details results from a randomized, multicenter, double-blind, placebo-controlled clinical trial evaluating the effectiveness of the inFoods®?
Ibs test in identifying patient-specific dietary IBS triggers and providing targeted food elimination to reduce IBS symptoms. Large Multicenter Study Demonstrates Clinically Meaningful Pain Reduction IBS affects an estimated 10% to 15% of adults in the United States and is known to significantly reduce quality of life and work productivity.
